Evidence map›Paper›PMID 40667824›Full record

ReviewJournal of medical virology2025

Viral Enhancers Orchestrate Kaposi's Sarcoma-Associated Herpesvirus Transcription.

Nilabja Roy Chowdhury, Meir Shamay

Abstract readReview
In one paragraph

Review in Journal of medical virology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Nilabja Roy ChowdhuryDaniella Lee Casper Laboratory in Viral Oncology, Azrieli Faculty of Medicine, Bar-Ilan University, Safed, Israel.ORCID 0000-0003-1262-4972
Meir ShamayDaniella Lee Casper Laboratory in Viral Oncology, Azrieli Faculty of Medicine, Bar-Ilan University, Safed, Israel.ORCID 0000-0003-0223-2852

Funding

This work was supported by grants from the Israel Science Foundation (https://www.isf.org.il) to M.S. (1365/21) and the Israel Cancer Research Fund (https://www.icrfonline.org/) to M.S. (23-101-PG).
6 · The paper itself

Abstract

Kaposi's sarcoma-associated herpesvirus (KSHV), the etiological agent of Kaposi's sarcoma and other lymphoproliferative disorders, presents a delicate balance between host cell manipulation, and orchestrating its transcriptional repertoire. Like all herpes viruses, the virus can reside in latency, expressing only a handful of proteins or launch a lytic program that expresses over 80 proteins responsible for the generation and release of new virions. Enhancers, as their name suggests, can enhance the transcription rate from a promoter depending on the cellular environment and tissue. While the promoters in KSHV have been extensively studied, the enhancers were only recently identified. Here we will describe our current view on KSHV enhancers.

Indexed as

Enhancer Elements, GeneticGene Expression Regulation, ViralHerpesvirus 8, HumanTranscription, GeneticHumansPromoter Regions, GeneticSarcoma, KaposiViral ProteinsVirus LatencyViral Proteinsenhancerherpes virusKSHVpromoterterminal repeattranscription

Identifiers

PMID40667824
PMCPMC12265388

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.